- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Multicentre
- Study aim: To investigate the effect of compassionate use of plitidepsin as an antiviral therapy in immunocompromised COVID-19 patients with underlying haematological malignancies or solid tumors, particularly those who have undergone anti-CD20 therapies
- Number of participants enrolled: 54
- Study enrolling from to
- Study includes follow-up for 1 month
- Standardisation: 0
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Plitidepsin
External Links
Other information
Funders:
- PharmaMar S.A.
- Hospital Universitario QuironSalud Madrid
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to